Heart failure & cardiomyopathiesSecondary analysis
Anaemia in Patients With Heart Failure and Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the FINEARTS-HF Trial
- Prespecified secondary analysis of the FINEARTS-HF randomised trial
Authors' conclusion
Finerenone reduces the risk of clinical outcomes regardless of anaemia status.
Study context
- Population
- Patients with HFmrEF/HFpEF enrolled in FINEARTS-HFanalysed
- Participants
- 5,665 patients
- Comparison
- Finerenone effect by anaemia status
- Anaemian = 1,584
- Primary endpoint
- Composite of:
- Total (first and recurrent) HF events
- CV death
Primary result
As reported in the abstract
Effect of finerenone on primary endpoint by anaemia status
Finerenone vs No anaemiaRelative risk (95% CI)
anaemia
0.89(0.73–1.10)
no anaemia
0.76(0.64–0.91)
Further findings
Event rate, per 100 person-years
| Outcome | Anaemia | No anaemia | RR (95% CI) | |
|---|---|---|---|---|
| Primary endpoint risk, anaemia vs no anaemia | 24.3 (95% CI 21.9–26.9) | 13.1 (95% CI 12.0–14.3) | 1.67 (1.45–1.92) | |
| 0.512Relative risk (log scale) |
Primary endpoint risk, anaemia vs no anaemia
- Persistent anaemia had worse outcomes than resolved anaemia; new-onset anaemia had worse outcomes than no new anaemia
Resolution and new onset of anaemia
- Finerenone did not increase resolution of anaemia or prevent new-onset anaemia
Original publication
Anaemia in Patients With Heart Failure and Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the FINEARTS-HF Trial. Eur J Heart Fail. Published 16 May 2025. doi:10.1002/ejhf.3682
Summarised from the published abstract; every number is checked against it